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abSTRaCT
Background and aims: The aim of this study was to compare blood glucose and plasma insulin profiles after bolus insulin infusion by a patch pump versus a conventional pump, directly after placement and after day 3 of use.
Materials and methods: Twenty patients with type 1 diabetes came in for two blocks of visits: one block of two visits while wearing the OmniPod Insulin Pump (PP) and one block of two visits while wearing the Medtronic Paradigm Pump (CP). Patients administered an identical mealtime insulin bolus of at least 6 IU.
Results: For PP maximum glucose levels were 28.7% lower on day 3 (P=0.020), when maximum insulin levels were 30.3% higher (P=0.002). For CP maximum glucose levels were 26.5% lower on day 3 (P=0.015), when maximum insulin levels were 46.4% higher (P=0.003).
Mean glucose levels were significantly lower on day 3 for PP (168. Conclusion: Postprandial glycaemic excursions were lower on day 3 of catheter wear time, but there were no differences between patch pumps and conventional pumps. These findings support that catheter wear time plays an important role in insulin absorption.
Patch pump vs. conventional pump

57
InTRODuCTIOn
Until recently all insulin pumps consisted of a needle inserted into the subcutaneous tissue, a housing (containing the insulin, electronics, pump and batteries) and a catheter connecting these two parts. Recently patch pumps were developed, to be carried directly on the skin, without the need to insert a needle manually and without a visible catheter (1) (2) (3) . Internally these patch pumps still employ a catheter with a length of about 50 mm, substantially less than the 600 mm of catheter tubing used most often with catheter based pumps. It has been hypothesized that insulin catheters could influence insulin delivery (4) . However, to our knowledge, there are no published studies investigating insulin absorption with these two types of insulin pumps with markedly different catheter lengths. For closed loop studies, in which insulin pumps are combined with subcutaneous glucose sensors to automatically compute and administer appropriate amounts of insulin to maintain euglycaemia, it is relevant to know if patch pumps (PP) and conventional insulin pumps (CP) induce different insulin absorption rates and to investigate reproducibility of insulin absorption. A reproducible and rapid absorption of the administered insulin is paramount to establish a successful Artificial Pancreas (AP). Additionally, recent evidence suggests that the duration the insulin catheter usage (wear time) influences the speed of insulin absorption from the subcutaneous tissue, in that the time to maximal insulin levels seems to decrease with a longer wear time (5, 6) . It is important to gain knowledge on the evolution of insulin pharmacokinetics with the progression of wear time of insulin pumps, since Model Predictive Control algorithms rely on adequate and accurate modelling of pharmacokinetic parameters. The aim of this study therefore, was to detect differences in postprandial glucose profiles and plasma insulin profiles after bolus insulin administration by a patch pump versus a conventional insulin pump while at the same time investigating the effect of catheter wear time on these profiles in patients with type 1 diabetes. After the first visit in a block, patients were discharged and continued to wear the pump at home to return after 48 hours for a second visit with the same pump to allow for the assessment of the effect of wear time. Upon completion of a block the pump would be removed and patients returned to their usual insulin therapy. For the visits, patients reported to the Clinical Research Center (CRC) in a fasting state at 8 a.m. when blood sampling for glucose and plasma insulin determinations were started to record baseline values. If baseline blood glucose was >140 mg/dL, glycaemia was stabilized to euglycaemic levels (65-140 mg/dL) by intravenous administration of insulin and the start of the study was delayed. Patients received breakfast at 9 a.m., of a composition which was customary to them, accompanied by their individually determined mealtime insulin bolus via the PP or CP (figure 1b). However, in all cases the meal bolus was at least 6 U to ensure sufficient increases in insulinemia during the visits. On all study days for a given patient, the same insulin dose was applied to cover an identical breakfast. Patients were also not allowed to change their basal insulin rates during the trial. Blood was sampled for plasma insulin and blood glucose determination until 4.5 hours postprandially (once every 10 minutes for the first 2 h and subsequently every 15 minutes for the next 2.5 h ( figure 1B) ). Blood glucose levels were determined at the bedside by a laboratory method (YSI 2300 STAT PLUS; YSI Incorporated, Yellow Springs, OH). Heparinized plasma was frozen and stored for later determination of insulin levels using an insulin chemiluminescence assay Patients completed two blocks of 2 visits, totaling four study visits to the CRC. Two while wearing a conventional insulin pump (CP) and two while wearing a patch pump (PP). The two visits within one block, in which the same pumps were used, were 48 hours apart. Each visit took 5.5 hours to complete. B: Within each visit patients arrived at the CRC at 08.00. Blood samples for glucose and plasma insulin determination were collected every 15 min. The sampling rate was increased after the breakfast which was served to patients and continued until 4.5 hours postprandially.
METhODS
RESuLTS
Of the 20 included patients, one patient was unable to complete the second visit while wearing the patch pump.
Technical issues
There was technical failure of the Omnipod patch pump in 5 cases, in 1 case the Omnipod dislodged from the body of the participant. The catheter based pump had 1 technical failure. In all these cases the pumps were replaced and the entire block of two visits while wearing the affected pump was rescheduled.
Baseline levels
Baseline glucose concentrations needed to be stabilized in 23 out of 79 visits (6.1%, 
DISCuSSIOn
In this study we showed that insulin absorption is significantly faster on day 3 of use of an insulin pump, resulting in lower postprandial glucose values. These findings suggest that the wear time of the insulin catheter determines insulin absorption. The absence of any difference between PP and CP suggests that the influence of tubing length, if any, is negligible. These findings are corroborated by studies investigating the trauma induced by insertion of the catheter tip by a needle into the subcutaneous fat. After insertion marked increases in adipose tissue blood flow have been demonstrated up to two days after insertion, combined with faster absorption of insulin up to four days after insertion (5). This is in line both with the observed timeframes in this study and with our finding that pharmacokinetic parameters as time-to-peak and maximum insulin levels changed, but AUC did not. In other words, there was no difference in total absorbed insulin. Insulin was absorbed more swiftly if the infusion site was 3 days old. The current advice to change insulin catheters after 3 days is supported by literature (7), however patients often use their catheters longer and further research is needed to determine the effects of this increased wear time.
The change in insulin pharmacokinetics over the course of the wear time of insulin pumps, and more specifically over the course of the ageing insertion site, could influence closed loop therapy. Indeed, we conducted this trial with the primary aim to the gain knowledge to improve closed loop model predictive control algorithms.
Control algorithms could be made aware of a catheter change and could thus anticipate upon changes in insulin pharmacokinetics, thereby possibly improving glycaemic control during closed loop. The same is true for automated bolus calculators, which could use this information to suggest a more appropriate bolus amount. In addition, the field of closed loop control is investigating a "single-port" approach (8, 9) , in which the glucose sensor necessary for closed loop control is physically coupled to the insulin infusion catheter and reside within the same infusion site. With glucose sensors having a lifetime ranging from 5 to 7 days, which therefore could in principle extend the time the catheter-sensor combination remains in situ for this amount of time, insulin pharmacokinetics could change even more over time than we were able to measure in this study.
This study has demonstrated that as time progresses from the moment of catheter placement, insulin is absorbed more quickly from the infusion site. This study has also shown that these changes in insulin pharmacokinetics are clinically relevant, resulting in less pronounced postprandial glucose curves with older catheters. Patients and physicians should be aware of the temporarily diminished insulin absorption which occurs when changing insulin infusion sites. This knowledge could also help to improve upon closed loop control algorithms which could more accurately predict the effects of insulin infusion, bringing us a small step closer to a safe and effective artificial pancreas.
